2125956-92-3
Chemical Structure
SNT-5382
- CAS 番号: 2125956-92-3
- Formula:C20H24Cl2FN3O2S
- Molecular Weight:460.39
InChIKey: ZBRFTAUBDWUMEJ-ULPVBNQHSA-N
SMILES: CC1=C(C2=CC(S(C)(=O)=O)=CC=C2)C3=NC(C)=CC=C3N1C/C(F)=C/CN.Cl.Cl
Biological Activity: SNT-5382 is a lysyl oxidase family (LOX) inhibitor and anti-fibrotic agent. SNT-5382 binds to the LTQ cofactor of LOXL2 and inhibits the enzymatic activities of LOXL3, LOXL4, LOXL1, CYP2C9, and CYP2C19. SNT-5382 reduces cardiac and liver fibrosis as well as collagen crosslinks, and improves cardiac function. SNT-5382 can be used for the research of heart failure, myocardial infarction, and nonalcoholic steatohepatitis-related liver fibrosis[1][2].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SNT-5382 | 99.93% | SNT-5382 is a lysyl oxidase family (LOX) inhibitor and anti-fibrotic agent. SNT-5382 binds to the LTQ cofactor of LOXL2 and inhibits the enzymatic activities of LOXL3, LOXL4, LOXL1, CYP2C9, and CYP2C19. SNT-5382 reduces cardiac and liver fibrosis as well as collagen crosslinks, and improves cardiac function. SNT-5382 can be used for the research of heart failure, myocardial infarction, and nonalcoholic steatohepatitis-related liver fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Perryman L, et al. The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement. Sci Rep. 2025;15(1):22653. Published 2025 Jul 2. [Content Brief]
- [2]. Findlay AD, et al. Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof, WO, WO2017136870A1, 2017-08-17.
